PRESS RELEASE
Feb 03, 2026
BioStem Technologies Highlights Alignment with FDA's Openness to Bayesian Statistical Approaches in Clinical Research
Jan 21, 2026
BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings' Surgical and Wound Care Business
Jan 07, 2026
BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
Dec 18, 2025
BioStem Technologies Products Placed on "12-Month Status Quo Period" List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
Dec 10, 2025
BioStem Technologies® to Debut American Amnion(TM) at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference
Nov 25, 2025
BioStem Technologies Expands Product Access in Medicaid
Nov 13, 2025
BioStem Technologies Reports Third Quarter 2025 Financial Results
Nov 13, 2025
BioStem Technologies Announces Filing of Restated Financial Statements
Nov 05, 2025
BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes
Nov 05, 2025
BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters